Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chenghui Lu

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Frontiers in Endocrinology|June 18, 2026
Construction and validation of a nomogram model for predicting response to initial radioiodine therapy in differentiated thyroid cancer patients using serum cytokines combined with serum thyroglobulinGuohua Qin, AiQiang Dong, Ning Wang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 7, 2025
Reflective analysis on the current <sup>131</sup>I adjuvant therapy indications in intermediate- and high-risk differentiated thyroid cancerYuqing Sun, Yihan Zhao, Di Sun, et al.
Molecules (Basel, Switzerland)|October 14, 2022
First Discovery of Cholesterol-Lowering Activity of Parthenolide as NPC1L1 InhibitorWenjing Liu, Bing Liang, Jun Zeng, et al.
Future Oncology (London, England)|August 20, 2025
Clinical outcome and influencing factors of differentiated thyroid cancer with biochemical incomplete responseCongcong Wang, Guohua Qin, Shuhui Wang, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Frontiers in Endocrinology|June 18, 2026
Construction and validation of a nomogram model for predicting response to initial radioiodine therapy in differentiated thyroid cancer patients using serum cytokines combined with serum thyroglobulinGuohua Qin, AiQiang Dong, Ning Wang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 7, 2025
Reflective analysis on the current <sup>131</sup>I adjuvant therapy indications in intermediate- and high-risk differentiated thyroid cancerYuqing Sun, Yihan Zhao, Di Sun, et al.
Molecules (Basel, Switzerland)|October 14, 2022
First Discovery of Cholesterol-Lowering Activity of Parthenolide as NPC1L1 InhibitorWenjing Liu, Bing Liang, Jun Zeng, et al.
Future Oncology (London, England)|August 20, 2025
Clinical outcome and influencing factors of differentiated thyroid cancer with biochemical incomplete responseCongcong Wang, Guohua Qin, Shuhui Wang, et al.
Pageof 5